The label for Metformin Hydrochloride has been updated to include a boxed warning regarding lactic acidosis, effective 2025-08-18. This critical revision highlights that postmarketing cases of metformin-associated lactic acidosis have led to severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning also notes that the onset of metformin-associated lactic acidosis is often subtle, making early recognition challenging.
Details of the Boxed Warning
The new boxed warning for Metformin Hydrochloride specifically addresses the risk of lactic acidosis. It states that postmarketing cases of metformin-associated lactic acidosis have resulted in severe consequences, including death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning further emphasizes that the onset of metformin-associated lactic acidosis is often subtle, which can complicate timely diagnosis and intervention. This subtle onset means that patients may not present with clear symptoms until the condition is advanced, necessitating a high index of suspicion from healthcare providers.
What this means
The addition of a boxed warning for lactic acidosis on the Metformin Hydrochloride label underscores the serious and potentially fatal risks associated with this adverse event. Healthcare providers must be acutely aware of the characteristics of metformin-associated lactic acidosis, including its often subtle onset and severe manifestations such as hypothermia, hypotension, and resistant bradyarrhythmias. Vigilant monitoring for symptoms and patient education on the signs of lactic acidosis are crucial for early detection and management, aiming to mitigate the risk of death and other severe complications associated with Metformin Hydrochloride use.
Source
This information regarding the label revision for Metformin Hydrochloride, specifically the addition of a boxed warning, was sourced from the FDA. The update was effective 2025-08-18 and is available on dailymed.nlm.nih.gov.